With the results of a recent trial, Abbott is seeking an expanded indication from the FDA for its CardioMEMS device, intended to prevent hospitalizations in patients with heart failure. It’s also hoping to win over national coverage from CMS.
After a difficult premarket approval process and tenuous relationship with the FDA, Atlanta’s CardioMEMS received a mixed message from an FDA advisory panel on its CHAMPION HF Pressure Measurement System, an implantable sensor monitor to help guide treatment in patients with congestive heart failure. The panel voted unanimously that the device was safe, the majority […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Wanna buy a medical device startup? A down payment would be nice. As competition for medical device acquisitions heats up, Medtronic Inc. (NYSE:MDT) and Boston Scientific Corp. (NYSE:BSX) are redeeming early bets on promising startups.
Earnings reports are good ways to measure a company's financial performance. What they're less useful for is gauging a company's confidence. You know... Mojo. Swagger. Groove. And here's what I see: Medtronic Inc. (NYSE:MDT) always had it. Boston Scientific Corp. (NYSE:BSX) has lost it. And St. Jude Medical Inc. (NYSE: STJ) is feeling it.
St. Jude Medical Inc. (NYSE: STJ) said Tuesday it will spend $60 million to acquire a 19-percent stake in CardioMEMS, a company developing wireless heart monitoring technology for heart failure.
Highlights of the important and the interesting from the world of healthcare: The danger of price transparency: Congress is debating a bill that would bring more price transparency to healthcare, but Budget Director Peter Orszag says too much transparency may be a bad thing. “The markets for some health care services are highly concentrated, so […]
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.